Wall Street analyst estimates for Century Therapeutics, Inc. (IPSC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.12 | ||
| 2026-08-12 | $-0.17 | $-0.11 | -54.5% |
| 2026-05-13 | $-0.11 | $-0.15 | +26.7% |
| 2026-03-12 | $-0.25 | $-0.28 | +10.7% |
| 2025-11-13 | $-0.32 | $-0.39 | +17.9% |
| 2025-08-14 | $-0.38 | $-0.38 | +0.0% |
| 2025-05-15 | $0.89 | $-0.31 | +387.1% |
| 2025-03-19 | $-0.43 | $-0.45 | +4.4% |
Valuation Ratios
| Price / Book | 1.54 |
| EV / EBITDA | -1.61 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $5.2M | $2.2M | $6.6M | $109.2M |
| Cost of Revenue | $249000 | $1.8M | $4.6M | 0 | 0 | 0 | $13.1M |
| Gross Profit | -$249000 | -$1.8M | -$4.6M | $5.2M | $2.2M | $6.6M | $96.1M |
| Research & Development | $14.3M | $39.7M | $75.6M | $97.2M | $92.7M | $107.2M | $95.7M |
| Selling, General & Admin | $5.5M | $7.7M | $14.7M | $31.9M | $34.7M | $33.2M | $24.0M |
| Operating Expenses | $19.8M | $47.4M | $90.3M | $139.0M | $148.8M | $144.7M | $111.1M |
| Operating Income | -$20.0M | -$49.2M | -$94.9M | -$133.8M | -$146.5M | -$138.1M | -$15.0M |
| EBITDA | -$244.5M | -$51.4M | -$89.9M | -$121.2M | -$121.2M | -$111.5M | $3.5M |
| Interest Expense | 0 | $381000 | $1.3M | 0 | $540000 | 0 | 0 |
| Pre-tax Income | -$244.8M | -$53.6M | -$95.8M | -$130.8M | -$134.8M | -$124.8M | -$9.6M |
| Income Tax | 0 | 0 | $43000 | $91000 | $1.9M | $1.8M | -$68000 |
| Net Income | -$244.8M | -$53.6M | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
| EPS | $-4.49 | $-1.00 | $-1.74 | $-2.27 | $-2.30 | $-1.61 | $-0.11 |
| EPS (Diluted) | $-4.49 | $-1.00 | $-1.74 | $-2.27 | $-2.30 | $-1.61 | $-0.11 |
| Shares Outstanding (Diluted) | $54.8M | $54.8M | $55.0M | $57.8M | $59.3M | $78.6M | $86.6M |
Price
| Price | $1.86 |
| Market Cap | $161M |
| Exchange | NASDAQ |
| Country | US |
Related companies: COEP · CUE · EQ · GNTA · KPTI · MDCX · OSTX
Explore sector: Healthcare · Biotechnology
More sections of IPSC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks